Prognostic Impact of the Plasma Cell Labeling Index (LI) in Newly Diagnosed Myeloma Patients Treated with Thalidomide-Dexamethasone (Thal/Dex) or Lenalidomide-Dexamethasone (Len/Dex)

被引：0
|
作者：
Kapoor, Prasw Nt
Kumar, Shaji
Greipp, Philip R.
Laumann, Kristina M.
Mandrekar, Sumithra [1 ]
Rajkumar, S. Vincent [2 ]
Witzig, Thomas E. [3 ]
机构：
[1] Mayo Clin, Div Biostat, Rochester, MN USA
[2] Mayo Clin, Coll Med, Rochester, MN USA
[3] Mayo Clin, Rochester, MN USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：609 / 609
页数：1
相关论文
共 50 条
  • [1] Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma
    Gay, Francesca
    Hayman, Suzanne
    Lacy, Martha Q.
    Buadi, Francis
    Gertz, Morie A.
    Kumar, Shaji
    Dispenzieri, Angela
    Mikhael, Joseph R.
    Bergsagel, Leif
    Dingli, David
    Reeder, Craig B.
    Lust, John A.
    Russel, Stephen
    Roj, Vivek
    Zeldenrust, Steven R.
    Witzig, Thomas E.
    Fonseca, Rafael
    Kyle, Robert
    Greipp, Philip R.
    Stewart, A. Keith
    Rajkumar, S. Vincent
    [J]. BLOOD, 2009, 114 (22) : 1494 - 1495
  • [2] Combination therapy with thalidomide plus dexamethasone (THAL/DEX) for newly diagnosed myeloma (MM).
    Rajkumar, SV
    Hayman, SR
    Gertz, MA
    Dispenzieri, A
    Lacy, M
    Greipp, PR
    Geyer, S
    Itturia, N
    Fonseca, R
    Lust, JA
    Kyle, R
    Witzig, TE
    [J]. BLOOD, 2001, 98 (11) : 849A - 849A
  • [3] Thalidomide plus dexamethasone (Thal/Dex) and thalidomide alone (Thal) as first line therapy for newly diagnosed myeloma (MM).
    Rajkumar, SV
    Hayman, S
    Fonseca, R
    Dispenzieri, A
    Lacy, MQ
    Geyer, S
    Wellik, L
    Lust, JA
    Kyle, RA
    Greipp, PR
    Gertz, MA
    Witzig, TE
    [J]. BLOOD, 2000, 96 (11) : 168A - 168A
  • [4] Prediction of response to primary therapy with thalidomide-dexamethasone(Thal-DEX) for newly diagnosed multiple myeloma by gene expression profiling (GEP)
    Terragna, C.
    Renzulli, M.
    Remondini, D.
    Tagliafico, E.
    Roncaglia, E.
    Tosi, P.
    Zamagni, E.
    Tacchetti, P.
    Perrone, G.
    Ceccolini, M.
    Brioli, A. M.
    Martinelli, G.
    Baccarani, M.
    Cavo, M.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 177 - 177
  • [5] Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by Gene Expression Profiling (GEP)
    Terragna, C.
    Renzulli, M.
    Remondini, D.
    Tagliafico, E.
    Roncaglia, E.
    Tosi, P.
    Zamagni, E.
    Tacchetti, P.
    Perrone, G.
    Ceccolini, M.
    Brioli, A.
    Pallotti, M. C.
    Martinelli, G.
    Baccarani, M.
    Cavo, M.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 138 - 138
  • [6] EXTENDED TREATMENT WITH THE COMBINATION OF CARFILZOMIB (CFZ), LENALIDOMIDE (LEN), AND DEXAMETHASONE ( DEX) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
    Jakubowiak, A.
    Griffith, K.
    Dytfeld, D.
    Vesole, D.
    Jagannath, S.
    Anderson, T.
    Nordgren, B.
    Detweiler-Short, K.
    Lebovic, D.
    Stockerl-Goldstein, K.
    Jobkar, T.
    Wear, S.
    Al-Zoubi, A.
    Ahmed, A.
    Mietzel, M.
    Couriel, D.
    Kaminski, M.
    Hussein, M.
    Yeganegi, H.
    Vij, R.
    [J]. HAEMATOLOGICA, 2012, 97 : 115 - 115
  • [7] Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
    Rajkumar, SV
    Hayman, SR
    Lacy, MQ
    Dispenzieri, A
    Geyer, SM
    Kabat, B
    Zeldenrust, SR
    Kumar, S
    Greipp, PR
    Fonseca, R
    Lust, JA
    Russell, SJ
    Kyle, RA
    Witzig, TE
    Gertz, MA
    [J]. BLOOD, 2005, 106 (13) : 4050 - 4053
  • [8] Stringent complete response (sCR) in patients (pts) with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX).
    Jakubowiak, Andrzej J.
    Griffith, Kent A.
    Dytfeld, Dominik
    Vesole, David H.
    Jagannath, Sundar
    Anderson, Tara B.
    Nordgren, Brian K.
    Detweiler-Short, Kristen
    Lebovic, Daniel
    Stockerl-Goldstein, Keith
    Jobkar, Terri L.
    Wear, Sandra Marija
    Al-Zoubi, Ammar
    Ahmed, Asra Z.
    Mietzel, Melissa A.
    Couriel, Daniel R.
    Kaminski, Mark Stefan
    Hussein, Mohamad A.
    Yeganegi, Homa
    Vij, Ravi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
    Rajkumar, SV
    Hayman, S
    Lacy, MQ
    Dispenzieri, A
    Geyer, SM
    Kabat, B
    Zeldenrust, SR
    Kumar, S
    Greipp, PR
    Fonseca, R
    Lust, JA
    Russell, SJ
    Kyle, RA
    Witzig, TE
    Gertz, MA
    [J]. BLOOD, 2005, 106 (11) : 230A - 231A
  • [10] A randomized comparison of dexamethasone plus thalidomide (Dex/Thal) vs dex plus placebo (Dex/P) in patients (pts) with relapsing multiple myeloma (MM).
    Fermand, Jean-Paul
    Jaccard, Arnaud
    Macro, Margaret
    Uzunhan, Yurdagul
    Allard, Christian
    Castaigne, Sylvie
    Divine, Marine
    Mariette, Xavier
    Leblond, Veronique
    Chevret, Sylvie
    [J]. BLOOD, 2006, 108 (11) : 1017A - 1018A
12345